HK Stock Market Move | PEIJIA-B (09996) rose more than 6% in the morning session, with strong growth in neurointerventional products. The chairman plans to continue increasing his shareholding.

PEIJIA-B (09996) rose more than 6% in early trading, with a gain of 6.69% as of press time, to 6.06 Hong Kong dollars, with a turnover of 118.539 million Hong Kong dollars. On the news front, Peijia Medical released its annual performance, with the group achieving revenue of RMB 713 million, an increase of 15.82% year-on-year; shareholders' net loss narrowed by 10.28% year-on-year. The announcement showed that during the period, sales revenue of TAVR-related products increased by 11.6% year-on-year to RMB 290 million; sales revenue of neurointerventional products increased by 18.9% year-on-year to RMB 423 million, with a profit growth of 86.6% year-on-year to RMB 97.2 million in this segment. The company also stated that the executive director, CEO, and chairman of the board of directors, Dr. Zhang Yibo, through a company controlled by him, plans to continue purchasing company shares on the open market starting from March 26. The total expected cost of this shareholding increase is not expected to exceed HKD 15 million, and it is not ruled out that further increases in his shareholding in the company may be possible at an appropriate time according to applicable laws and regulations.